Fabry Disease
Conditions
Keywords
Agalsidase beta, alpha Galactosidase A, aGAL, rh aGAL, Fabry, GL3, Fabrazyme, dialysis, hemodialysis
Brief summary
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme. Fabrazyme is a drug that helps to breakdown and remove certain types of fatty substances called glycolipids. These glycolipids are normally present within the body in most cells. In Fabry disease, glycolipids build up in various tissues such as the liver, kidney, skin, and blood vessels because a-galactosidase A is not present, or is present in small quantities. The build up of glycolipid (globotriaosylceramide or GL-3) levels in these tissues in particular is thought to cause the clinical symptoms that are common to Fabry disease. This study is designed to verify that no loss of Fabrazyme occurs during simultaneous Fabrazyme infusion and hemodialysis in patients currently receiving Fabrazyme at a dose of 1.0 mg/kg every 2 weeks.
Interventions
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patient must provide signed, written informed consent prior to any study-related procedures being performed. * Patient is between 18 and 65 years of age, inclusive. * Patient has documented Fabry disease. * Patient has received bi-weekly 1 mg/kg infusions of Fabrazyme for at least 6 months prior to enrollment into the study. * Patient has not experienced moderate or severe infusion-associated reactions (IARs) from Fabrazyme infusions, which were also associated with a rate reduction, within 3 months prior to enrollment into the study. * Patient has been receiving chronic hemodialysis for treatment of end-stage renal insufficiency for at least 3 months prior to enrollment into the study. * Patient has good vascular access for hemodialysis. * Patient has not and will not have any other (investigational) drug(s) infused during their hemodialysis, and is expected to have a stable concomitant medication regimen at all PK assessments.
Exclusion criteria
* Patient's hemoglobin is \< 9 g/100 mL at Screening/Baseline. * Patient has a clinically significant organic disease or an unstable condition that, in the opinion of the Investigator, would preclude participation in the study. * Patient has a medical condition, serious intercurrent illness, or extenuating circumstance that would significantly decrease study compliance. * Patient has participated in a study employing an investigational drug within 30 days prior to the start of their participation in this study. * Patient is unwilling to comply with the requirements of the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Verify that no loss of Fabrazyme occurs during simultaneous Fabrazyme infusion and hemodialysis with a low-flux membrane. | — |
Secondary
| Measure | Time frame |
|---|---|
| Verify that no loss of Fabrazyme occurs during simultaneous Fabrazyme infusion and hemodialysis with a high-flux membrane. | — |
Countries
United States
Outcome results
None listed